Axa S.A. Scholar Rock Holding Corp Transaction History

Axa S.A.

$33.6 Billion
Q2 2025

A detailed history of Axa S.A. transactions in Scholar Rock Holding Corp stock. As of the latest transaction made, Axa S.A. holds 92,992 shares of SRRK stock, worth $2.71 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

92,992

Previous 105,960 12.24%

Holding current value

$2.71 Million

Previous $3.41 Million 3.32%

% of portfolio

0.01%

Previous 0.01%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$24.47 - $36.39 $317,326 - $471,905	-12,968 Reduced 12.24%	92,992 $3.29 Million
Q1 2025 May 15, 2025	SELL	$32.15 - $45.55 $4,308 - $6,103	-134 Reduced 0.13%	105,960 $3.41 Million
Q4 2024 Feb 14, 2025	SELL	$7.07 - $45.73 $1.88 Million - $12.2 Million	-266,261 Reduced 71.51%	106,094 $4.59 Million
Q3 2024 Nov 14, 2024	BUY	$7.63 - $9.71 $801 - $1,019	105 Added 0.03%	372,355 $2.98 Million
Q2 2024 Feb 25, 2025	BUY	$7.84 - $16.79 $2.09 Million - $4.47 Million	266,156 Added 250.87%	372,250 $3.1 Million
Q2 2024 Aug 14, 2024	BUY	$7.84 - $16.79 $1,622 - $3,475	207 Added 0.06%	372,250 $3.1 Million
Q1 2024 May 15, 2024	SELL	$13.2 - $17.76 $2.05 Million - $2.75 Million	-154,965 Reduced 29.4%	372,043 $6.61 Million
Q4 2023 Jul 16, 2024	BUY	$6.52 - $20.32 $1.01 Million - $3.15 Million	154,965 Added 41.65%	527,008 $9.91 Million
Q4 2023 Feb 14, 2024	SELL	$6.52 - $20.32 $83,156 - $259,161	-12,754 Reduced 2.36%	527,008 $9.91 Million
Q3 2023 Nov 14, 2023	BUY	$6.02 - $7.76 $288,984 - $372,511	48,004 Added 9.76%	539,762 $3.83 Million
Q2 2023 Aug 14, 2023	BUY	$5.79 - $9.11 $2.85 Million - $4.48 Million	491,758 New	491,758 $3.71 Million

Others Institutions Holding SRRK

# of Institutions

263

Shares Held

96.2M

Call Options Held

894K

Put Options Held

656K

View Full List

About Scholar Rock Holding Corp

Ticker SRRK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,640,600
Market Cap $1.51B
Description
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clini...

More about SRRK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

News

Stay updated on Axa S.A. with notifications on news.

Account